Article in Nano letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Julia A NowakDepartment of Biomedical Engineering, Boston University, Boston, Massachusetts 02215, United States.ORCID 0009-0009-3099-1638
Ezra ChoDepartment of Biomedical Engineering, Boston University, Boston, Massachusetts 02215, United States.ORCID 0009-0002-9399-2186
Meredith A DavisDepartment of Biomedical Engineering, Boston University, Boston, Massachusetts 02215, United States.ORCID 0009-0007-3822-8261
Siyi ZhengDepartment of Biomedical Engineering, Boston University, Boston, Massachusetts 02215, United States.ORCID 0000-0001-5514-2768
Lauren BellDepartment of Biomedical Engineering, Boston University, Boston, Massachusetts 02215, United States.ORCID 0009-0005-2839-1351
Fanrui ShaDepartment of Chemistry, Northwestern University, Evanston, Illinois 60208, United States.ORCID 0000-0001-8310-147X
Julian S MagdalenskiDepartment of Chemistry, Northwestern University, Evanston, Illinois 60208, United States.
Ashley LuiDepartment of Molecular Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, United States.ORCID 0000-0003-4090-4680
Marco NapoliDepartment of Molecular Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, United States.
Rana FalahatDepartment of Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, United States.
James J MuléDepartment of Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, United States.
Elsa R FloresDepartment of Molecular Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, United States.
Omar K FarhaDepartment of Chemistry, Northwestern University, Evanston, Illinois 60208, United States.ORCID 0000-0002-9904-9845
Michelle H TeplenskyDepartment of Biomedical Engineering, Boston University, Boston, Massachusetts 02215, United States.ORCID 0000-0003-4664-420X
Funding
TRANSLATIONAL RESEARCHP30CA076292 · NCI · UNIVERSITY OF SOUTH FLORIDA · PI Christine O'Connell · 1998 to 2026
$93.5M
Tissue, Pathology and BioinformaticsP50CA168536 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI MULE, JAMES J. · 2013 to 2017
$8.5M
Identification of non-coding RNAs to therapeutically target undruggable pathways in metastatic lung adenocarcinoma and squamous cell carcinomaR35CA197452 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI FLORES, ELSA R · 2016 to 2022
$6.4M
Translational Research in BiomaterialsT32EB006359 · NIBIB · BOSTON UNIVERSITY (CHARLES RIVER CAMPUS) · PI MARK W. GRINSTAFF, Michelle H Teplensky · 2009 to 2026
$4.2M
Integrated Program in Cancer and Data Science (ICADS)T32CA233399 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI William Douglas Cress, Elsa R Flores · 2019 to 2026
$1.7M
Synthetic Biology and Biotechnology (SB2) Predoctoral Training ProgramT32GM130546 · NIGMS · BOSTON UNIVERSITY (CHARLES RIVER CAMPUS) · PI CHEN, CHRISTOPHER S, KHALIL, AHMAD SAMIR · 2019 to 2023
$1.0M
Harnessing Nanoscale Presentation to Elucidate the Impact of Therapeutic Packaging on Innate ImmunityR35GM157326 · NIGMS · BOSTON UNIVERSITY (CHARLES RIVER CAMPUS) · PI Michelle H Teplensky · 2025 to 2026
$818k
BU Biological Design Center and STEM PathwaysFlorida Cancer Innovation FundNCINCI-NIHNCI NIH HHS P30 CA076292NCI NIH HHS P50 CA168536NCI NIH HHS R35 CA197452NCI NIH HHS T32 CA233399NIBIB NIH HHS T32 EB006359NIGMS NIH HHS R35 GM157326NIGMS NIH HHS T32 GM130546NIH-NIGMS R35GM157326The Hartwell Foundation and Synthetic Biology and Biotechnology Predoctoral Training GrantTranslational Research in BiomaterialsU.S. Army Contracting Command Award
6 · The paper itself
Abstract
Tumor overexpression of programmed death-ligand one (PD-L1) inhibits immune recognition. Existing monoclonal antibodies are fragile and penetrate tumors poorly, leading to variable outcomes. Antisense oligonucleotides (ASOs) can reduce PD-L1 expression, but require frequent high dosing due to rapid degradation, clearance, and poor uptake. To overcome this, we harnessed metal-organic frameworks (MOFs) to protect and deliver ASOs, reducing PD-L1 expression and elevating downstream immunity. With various PD-L1-specific ASOs loaded into NU-1000 MOFs, we sustain release up to 7 days, reduce PD-L1 expression across triple negative breast cancer and melanoma, and stimulate dendritic cells to amplify T cell proliferation. This dual tumor and immune cell modulation via MOF-mediated ASO delivery increases tumor caspase-3 expression and killing of human melanoma with patient tumor-infiltrating lymphocytes, and elongates
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Strengthening Antisense Oligonucleotide-Mediated Anti-Tumor Immunity via Metal-Organic Framework Nanoparticles. · full record | OpenQuestion